Of the 34 patients who had EGFR mutation-negative primary tumors, 6 (17.6%) developed a new EGFR mutation in the metastatic tumor (two with deletion mutations in exon 19, three with missense mutations in exon 21, and one with co-current mutations in exons 20 and 21). Here, EGFR is linked to metastatic neoplasm.